The importance of balancing toxicity and efficacy in chemotherapy focus on pemetrexed

American Journal of Cancer

Volumn 4, Issue 2, 2005, Pages 127-136

  Boyer, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; NAVELBINE; NUCLEOSIDE ANALOG; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; VINCA ALKALOID;

ALOPECIA; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DAILY LIFE ACTIVITY; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; ERYTHROCYTE COUNT; FATIGUE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEMATOLOGIC MALIGNANCY; HUMAN; HYDRATION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MONOTHERAPY; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; PATIENT CARE; PLEURA MESOTHELIOMA; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SENSORY NEUROPATHY; SKIN DISEASE; SOCIALIZATION; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WELLBEING;

EID: 22244459878     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200504020-00006     Document Type: Review

References (112)

1. Moinpour CM. Measuring quality of life: an emerging science. Semin Oncol 1994; 21 (5 Suppl 10): 48-60
2. Leplege A, Hunt S. The problem of quality of life in medicine. JAMA 1997; 278: 47-50
3. Bottomley A. The cancer patient and quality of life. Oncologist 2002; 7: 120-5
4. King CR, Haberman M, Berry DL, et al. Quality of life and the cancer experience: the state-of-the-knowledge. Oncol Nurs Forum 1997; 24: 27-41
5. World Health Organization. WHO chronicle. Geneva: WHO, 1947: 29
6. Lewis FM. Experienced personal control and quality of life in late-stage cancer patients. Nurs Res 1982; 31: 113-9
7. Young KJ, Longman AJ. Quality of life and persons with melanoma: a pilot study. Cancer Nurs 1983; 6: 219-25
8. Ferrans CE, Powers MJ. Quality of life index: development and psychometric properties. ANS Adv Nurs Sci 1985; 8: 15-24
9. Holmes S, Dickerson J. The quality of life: design and evaluation of a self-assessment instrument for use with cancer patients. Int J Nurs Stud 1987; 24: 15-24
10. Epstein AM, Hall JA, Tognetti J, et al. Using proxies to evaluate quality of life: can they provide valid information about patients' health status and satisfaction with medical care? Med Care 1989; 27 (3 Suppl.): S91-8
11. Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology (Huntingt) 1990; 4: 29-38
12. Aaronson NK. Quality of life research in cancer clinical trials: a need for common rules and language. Oncology (Huntingt) 1990; 4: 59-66
13. Hadorn DC, Hayes RD. Multitrait-multimethod analysis of health-related quality-of-life measures. Med Care 1991; 29: 829-40
14. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994; 12: 608-16
15. Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998; 317: 1191-4
16. Hainsworth JD, Mainwaring MG, Thomas M, et al. Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients. Clin Lung Cancer 2003; 4: 347-55
17. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-7
18. Pallis AG, Mavroudis D, Androulakis N, et al. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer: experience from a single center participating in a compassionate use program. Lung Cancer 2003; 40: 301-7
19. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46
20. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefinitib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58
21. Simon GR, Ruckdeschel JC, Williams C, et al. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single non-small-cell. Cancer Control 2003; 10: 388-95
22. Gridelli C, Maione P, Castaldo V, et al. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003; 89: 1827-9
23. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-9
24. Okamoto I, Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003; 40: 339-42
25. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003; 22: 179-81
26. Miya T, Ono Y, Tanaka H, et al. Radiation recall pneumonitis induced by gefitinib (Iressa): a case report [in Japanese]. Nihon Kokyuki Gakkai Zasshi 2003; 41: 565-8
27. Rabinowits G, Herchenhorn D, Rabinowits M, et al. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 2003; 14: 665-8
28. FDA approves Gleevec for pediatric leukemia. FDA Consum 2003; 37: 6
29. Velcade® (bortezomib) [online]. Available from URL: http://www.fda.gov/cder/ drμg/infopage/velcade/default.htm [Accessed 2003 Nov 16]
30. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus leucovorin (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract no. 3646]. Proc Am Soc Clin Oncol 2003; 22: 28
31. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract no. 1012]. Proc Am Soc Clin Oncol 2003; 22: 252
32. Van Laethem J-L, Raoul J-L, Mitry E, et al. Cetruximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-flurouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR): preliminary safety and efficacy results [abstract no. 1058]. Proc Am Soc Clin Oncol 2003; 22: 264
33. Pfister DG, Aliff TB, Kraus DH, et al. Current cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): preliminary evaluation of a new combined-modality paradigm [abstract no. 1993]. Proc Am Soc Clin Oncol 2003; 22: 495
34. Chan ATC, Hsu MM, Goh BC, et al. A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy [abstract no. 2000]. Proc Am Soc Clin Oncol 2003; 22: 497
35. Vega-Villegas E, Awada A, Mesia R, et al. A phase-I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) [abstract no. 2020]. Proc Am Soc Clin Oncol 2003; 22: 502
36. Kim ES, Mauer M, Tran HT, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report [abstract no. 2581]. Proc Am Soc Clin Oncol 2003; 22: 642
37. Gatzemeier U, Rosell R, Ramlau R, et al. Cetuximab (C225) in combination with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC) [abstract no. 2582]. Proc Am Soc Clin Oncol 2003; 22: 642
38. Robert F, Blumenschein G, Dicke F, et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer [abstract no. 2587]. Proc Am Soc Clin Oncol 2003; 22: 643
39. Kelly K, Hanna N, Rosenberg A, et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer [abstract no. 2592]. Proc Am Soc Clin Oncol 2003; 22: 644
40. Dolasetron mesylate injection (Anzemet® injection). Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 712-7
41. Granisetron hydrochloride injection (Kytril®). Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 2908-10
42. Ondansetran hydrochloride injection (Zofran®). Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 1697-701
43. Epoetin alfa (Epogen®) for injection. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 576-81
44. Epoetin alfa (Procrit®) for injection. Physicians' desk reference. Montvale (NJ): Medical Economics Inc, 2003: 2430-36
45. Darbepoetin alfa (Aranesp®) for injection. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 3516-9
46. Cisplatin (Platinol-AQ®) injection. Platneol AQ. prescribing information [online]. Available from URL: http://www.BMS.com [Assessed 2003 Dec 2]
47. Methotrexate sodium injection. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 3415-20
48. Karnofsky DA, Abelmann WH, Carrer LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-56
49. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
50. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trails in oncology. J Natl Cancer Inst 1993; 85: 365-76
51. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: The Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993; 29A Suppl. 1: S51-8
52. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001; 92: 595-600
53. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2: 472-83
54. Padilla GV, Presant C, Grant MM, et al. Quality of life index for patients with cancer. Res Nurs Health 1983; 6: 117-26
55. Ferrans CE, Powers MJ. Quality of life index: development and psychometric properties. ANS Adv Nurs Sci 1985; 8: 15-24
56. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-9
57. Matsumoto T, Ohashi Y, Morita S, et al. The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in Japanese patients with advanced non-small-cell lung cancer. Qual Life Res 2002; 11: 483-93
58. Fayers P, Bottomley A. Quality of life research within the EORTC: the EORTC QLQ-C30. European organisation for research and treatment of cancer. Eur J Cancer 2002; 38 Suppl. 4: S125-33
59. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771-5
60. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8
61. Ribaud P, Gouveia J, Bonnay M, et al. Clinical pharmacology and pharmacokinetics of cis-platinum and analogs. Cancer Treat Rep 1981; 65 Suppl. 3: 97-105
62. Yagoda A. Phase II trials with cis-dichlorodiammineplatinum (II) in the treatment of urothelial cancer. Cancer Treat Rep 1979; 63: 1565-72
63. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep 2004; 11: 559-95
64. Carboplatin (Paraplatin®) for injection. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 1126-9
65. Yarbro CH. Carboplatin: a clinical review. Semin Oncol Nurs 1989; 5: 63-9
66. Oxaliplatin (Eloxatin®) for injection. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 2999-3003
67. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005; 39: 128-35
68. Belani CP. Recent updates in the cliniclinicalcal use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Semin Oncol 2004; 31: 25-33
69. Grothey A, Goetz MP. Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer 2004; 4: S37-42
70. Paclitaxel (Taxol®) injection. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2002: 1129-38
71. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794-847
72. Rowinsky EK. The development and clinical utility of the taxane class of an-timicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353-74
73. Docetaxel (Taxotere®) for injection concentrate. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 773-9
74. Belani CP. Doxatel in combination with platinums in patients with advanced non small-cell lung cancer. Oncology (Huntingt) 1997; 11: 42-5
75. Antoine EC, Rixe O, Auclere G. Doxatel: a review of its role in breast cancer treatment. Am J Clin Oncol 1997; 20: 429-32
76. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 1996; 6: 443-57
77. Eisenberger MA, De Wit R, Berry W, et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC) [abstract no. 4]. J Clin Oncol 2004; 22: 14S
78. Gemcitabine (Gemzar®) for injection. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 1837-42
79. Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine, and vinorelbine in locally advanced or metastatic non-small-cell cancer: a phase I study. Ann Oncol 1997; 8: 1045-8
80. Castellano D, Lianes P, Paz-Ares L, et al. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 1998; 9: 457-9
81. Fountzilas G, Stathopoulos G, Nicolaides C, et al. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 475-8
82. Fountzilas G, Nicolaides C, Bafaloukos D, et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Cancer Invest 2000; 18: 503-9
83. Kunikane H, Kurita Y, Watanabe K, et al. A study of the combination of gemcitabine hycrochloride (LY188011) and cisplatin in non-small-cell lung cancer: a 3-week schedule. Int J Clin Oncol 2001; 6: 284-90
84. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-91
85. Svancorova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: 556-9
86. Soto Parra H, Cavina R, Latteri F, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002; 13: 1080-6
87. Lim N, Lara Jr PN, Lau DH, et al. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest 2003; 21: 7-13
88. Donadio M, Ardine M, Berruti A, et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 2003; 52: 147-52
89. Capecitabine (Xeloda®) tablets. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 2952-9
90. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27: 23-44
91. Vinorelbine tartarate (Navelbine®) injection. Physicians' desk reference. Montvale (NJ): Medical Economics Co. Inc., 2003: 1597-600
92. Gregory RK, Smith IE. Vinorelbine: a clinical review. Br J Cancer 2000; 82: 1907-13
93. Boyer MJ, Rivory LP, Clarke SJ. Pemetrexed: single agent and combination phase I study overview. Semin Oncol 2002; 29 Suppl. 18: 18-23
94. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18: 1748-57
95. Bunn P, Paoletti P, Niyikiza C, et al. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite [abstract]. Proc Am Soc Clin Oncol 2001; 20: 300
96. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. A phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44
97. Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single-blinded study of pemetrexed + cisplatin vs cisplatin alone in chemonaive patients with malignant pleural mesothelioma [abstract no. 5]. Proc Am Soc Clin Oncol 2002; 21: 2a
98. Liepa A, Rusthoven JJ, Denham C, et al. Clinical benefit algorithm for malignant pleural mesothelioma: results from a randomized trial of pemetrexed plus cisplatin versus cisplatin [abstract no. 475]. Program and abstracts of the 27th Congress of the European Society for Medical Oncology; 2002 Oct 18-22; Nice, France
99. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21: 1556-61
100. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20: 3533-44
101. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 1194
102. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed sodium (ALIMTA, LY231514) in chemotherapy-näive patients with advanced nonsmall cell lung cancer. Ann Oncol 2002; 13: 737-41
103. Lind MJ, Smith IE, Coleman RE, et al. Phase II study of MTA (LY213514) in patients (pts) with locally recurrent or metastatic breast cancer (LR/MBC) [abstract no. 433]. Proc Am Soc Clin Oncol 1998; 17: 433a
104. Theodoulou M, Llombart A, Cruciani G, et al. Pemetrexed disodium (Alimta, LY231514, MTA) in locally advanced or metastatic breast cancer (MBC) patients (pts) with prior anthracycline or anthracenedione and taxane treatment: phase II study [abstract no. 506]. Proc Am Soc Clin Oncol 2000; 19: 506a
105. Spielmann M, Martin M, Namer M, et al. Activity of pemetrexed (Alimta, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001; 2: 47-51
106. Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999; 17: 3009-16
107. Misset J-L, Gamelin E, Campone M, et al. Pemetrexed/oxaliplatin (LOHP) combination: results of a phase I study in metastatic solid tumors [abstract no. 427]. Proc Am Soc Clin Oncol 2002; 21: 107a
108. Johnson T, Hammond L, Johnson R, et al. Phase I and pharmacokinetic study (PK) of the multitargeted antifol LY231514 (MTA) in combination with irinotecan (CPT-11) [abstract no. 659]. Proc Am Soc Clin Oncol 1999; 18: 172a
109. Millward M, Clarke S, Beale P, et al. Phase I trial of pemetrexed (Alimta™) and vinorelbine in patients (pts) with advanced cancer [abstract no. 2102]. Proc Am Soc Clin Oncol 2001; 20: 88b
110. Johnson T, Schwartz D, McCune D. A phase I dose escalation study of the multitargeted antifolate, LY231514 (MTA) in combination with 5-fluorouracil (5-FU): dependence of toxicity on schedule of 5-FU administration [abstract]. Ann Oncol 1998; 9: 613a
111. Thodtmann R, Dumez H, Depenbrock H, et al. Clinical and pharmacokinetic phase I study of MTA (multi-targeted antifolate, LY231514) and paclitaxel (P) in patients with solid tumors administered every 21 days [abstract no. 885]. Proc Am Soc Clin Oncol 1999; 18: 230a
112. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA™) and cisplatin: a multicenter phase II trial. Ann Oncol 2000; 11: 435-40